Supernus Pharmaceuticals, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €1.06B +12.8% €327.08M +29.4% 30.7% +0.039 pp N/A N/A
    (estimated) €942.72M +14.1% €252.76M +56.3% 26.8% +0.072 pp N/A N/A
    (estimated) €826.03M +14.1% €161.70M +69.5% 19.6% +0.064 pp N/A N/A
    (estimated) €723.77M +21.9% €95.39M +14.3% 13.2% -0.0087 pp N/A N/A
    (estimated) €593.89M +5.2% €83.42M +32.4% 14.0% +0.029 pp N/A N/A
    €564.50M +8.9% €63.00M +5,512.8% 11.2% +0.11 pp €147.28M +54.7% 26.1% +0.077 pp
    €518.19M -8.9% €1.12M -97.8% 0.2% -0.089 pp €95.22M -4.8% 18.4% +0.0081 pp
    €569.12M +15.1% €51.78M +13.6% 9.1% -0.0012 pp €100.00M -9.2% 17.6% -0.047 pp
    €494.52M +11.4% €45.57M -57.9% 9.2% -0.15 pp €110.18M -8.9% 22.3% -0.050 pp
    €443.87M +32.5% €108.28M +12.3% 24.4% -0.044 pp €120.99M -2.8% 27.3% -0.099 pp
    €335.00M -3.9% €96.43M +1.9% 28.8% +0.016 pp €124.42M +12.4% 37.1% +0.054 pp
    €348.77M +35.3% €94.67M +93.8% 27.1% +0.082 pp €110.74M +11.3% 31.8% -0.069 pp
    €257.79M +40.6% €48.86M -37.2% 19.0% -0.23 pp €99.51M +70.5% 38.6% +0.068 pp
    €183.39M +48.9% €77.81M +550.8% 42.4% +0.33 pp €58.35M +99.9% 31.8% +0.081 pp
    €123.19M +18.3% €11.95M -29.5% 9.7% -0.066 pp €29.19M +311.1% 23.7% +0.17 pp
    €104.10M +915.4% €16.95M -121.5% 16.3% +7.8 pp €7.10M -115.0% 6.8% +4.7 pp
    €10.25M +712.1% -€78.70M +99.4% -767.7% +24 pp -€47.42M +19.7% -462.6% +27 pp
    €1.26M +84.3% -€39.48M -182.6% -3,127.3% -100 pp -€39.62M +30.8% -3,138.2% +13 pp
    €684.92K +657.5% €47.77M -245.6% 6,974.2% +430 pp -€30.28M +10.1% -4,420.9% +260 pp
    €90.41K -99.7% -€32.81M -8,461.5% -36,285.8% -360 pp -€27.51M -1,063.3% -30,424.5% -300 pp
    €32.35M +326.7% €392.36K -101.4% 1.2% +3.8 pp €2.86M -111.3% 8.8% +3.4 pp
    €7.58M -€28.56M -376.7% -€25.18M -332.1%

    Notifications